Why the study?
Does MitraClip implantation reduce mitral regurgitation severity and improve symptoms in high-surgical-risk patients with severe mitral regurgitation?
Does MitraClip implantation reduce mitral regurgitation severity and improve symptoms in high-surgical-risk patients with severe mitral regurgitation?
MitraClip implantation is a safe and effective treatment for reducing mitral regurgitation and improving symptoms in high-surgical-risk patients, though a compromise between MR reduction and avoiding mitral stenosis is often required, particularly in functional MR.
Answers are grounded in this paper and cite their sources.
Supports MitraClip feasibility in high-surgical-risk severe MR; leaves open need for RCTs to confirm benefit over alternatives.
BACKGROUND: Percutaneous edge-to-edge mitral valve repair with the MitraClip(®) was shown to be a safe and feasible alternative compared to conventional surgical mitral valve repair. Herein is reported our experience on MitraClip(®) for high-risk surgical candidates with severe mitral regurgitation (MR). METHODS AND RESULTS: Patients with severe MR (3 or 4+) and high operative risk were considered for MitraClip(®) implantation. Device success was defined as placement of 1 or more MitraClips(®) with reduction of MR to ≤2+. Patients were followed up clinically and with echocardiography at 1 year. A total of 27 patients with severe MR (age, 74±12 years; 17 male; logistic EuroSCORE, 27±12; left ventricular ejection fraction, 40±17%) were treated. Fifty-six percent of MR was degenerative and 44% was functional. Device success was 93% with 14 patients receiving 2 clips. MR severity was reduced from 3.5±0.5 to 1.7±0.8 (P<0.001); New York Heart Association class improved from 3.1±0.4 to 2.0±0.8 (P<0.001). In 45% of functional and in 29% of degenerative MR patients, to avoid mitral stenosis, additional MitraClip(®) implantation was not attempted, with resultant transmitral mean gradient of 4.9±1.6mmHg vs. 3.1±1.4mmHg, respectively (P=0.01). CONCLUSIONS: MitraClip(®) was shown to be an effective and safe treatment for patients with both functional and degenerative MR. Inability to obtain a greater reduction of MR was the consequence of borderline transmitral gradient requiring a compromise to avoid mitral stenosis, particularly in the functional MR patients.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: